Speaker Credentials
MBS student
Speaker Credentials
BS
College
College of Allopathic Medicine, MBS
Medical Specialty
Hematology
Format
Poster
Start Date
November 2024
End Date
November 2024
Track
4
Abstract
Objective This study evaluates the synergistic effects of the anticancer drugs Imatinib and Dasatinib in combination with Inecalcitol, a metabolite of vitamin D, on CML cell lines. Background Tyrosine kinase inhibitors (TKIs) has emerged as a popular treatment for chronic myeloid leukemia (CML), increasing patient outcomes. Vitamin D has anti-proliferative, pro-apoptotic, and anti-angiogenic effects, therefore it can be considered a potential cancer-preventative agent. Method AR-230, KCL-22, LAMA-84S, and U-937 cell lines were grown in T25 conical flasks for 48 hours at 37°C before transferring to a 96-well plate. Cells were treated with varying combinations of Inecalcitol, Imatinib, and Dasatinib. Cell death was determined by colorimetric measurement at 595 nM using ThermoFisher MTT assay protocol. Results With fixed concentrations of Imatinib (0.325 μM) and Dasatinib (0.456 nM), varying concentrations of Inecalcitol showed no anti-proliferative effect on the KCL-22 cell line (p-value > 0.31, 0.20). For equivalent treatments, we observed no anti-proliferative effect on the U-937 cell line (p-value > 0.40, 0.45). AR-230 exhibited maximal anti-proliferative effect with combined treatment of Imatinib with Inecalcitol (22.4%, p-value LAMA-84S exhibited maximal anti-proliferative effect with combined treatment of Imatinib and Inecalcitol (54.9%, p-value Conclusion The study suggests that Imatinib and Dasatinib show synergistic effects with Inecalcitol on cells that respond to TKIs. We predict the varying degrees of anti-proliferative effects seen with combinatory treatments differ between cell metabolism. Grants Health Public Divisions Intramural Research Grant
Included in
Synergistic Effects of Inecalcitol with Imatinib and Dasatinib on Chronic Myeloid Leukemia Cell lines
Objective This study evaluates the synergistic effects of the anticancer drugs Imatinib and Dasatinib in combination with Inecalcitol, a metabolite of vitamin D, on CML cell lines. Background Tyrosine kinase inhibitors (TKIs) has emerged as a popular treatment for chronic myeloid leukemia (CML), increasing patient outcomes. Vitamin D has anti-proliferative, pro-apoptotic, and anti-angiogenic effects, therefore it can be considered a potential cancer-preventative agent. Method AR-230, KCL-22, LAMA-84S, and U-937 cell lines were grown in T25 conical flasks for 48 hours at 37°C before transferring to a 96-well plate. Cells were treated with varying combinations of Inecalcitol, Imatinib, and Dasatinib. Cell death was determined by colorimetric measurement at 595 nM using ThermoFisher MTT assay protocol. Results With fixed concentrations of Imatinib (0.325 μM) and Dasatinib (0.456 nM), varying concentrations of Inecalcitol showed no anti-proliferative effect on the KCL-22 cell line (p-value > 0.31, 0.20). For equivalent treatments, we observed no anti-proliferative effect on the U-937 cell line (p-value > 0.40, 0.45). AR-230 exhibited maximal anti-proliferative effect with combined treatment of Imatinib with Inecalcitol (22.4%, p-value LAMA-84S exhibited maximal anti-proliferative effect with combined treatment of Imatinib and Inecalcitol (54.9%, p-value Conclusion The study suggests that Imatinib and Dasatinib show synergistic effects with Inecalcitol on cells that respond to TKIs. We predict the varying degrees of anti-proliferative effects seen with combinatory treatments differ between cell metabolism. Grants Health Public Divisions Intramural Research Grant